Shaanxi Maike Aote Pharmaceutical Technology

Shaanxi Maike Aote Pharmaceutical Technology, also known as Maccote, is a clinical-stage biotechnology company based in Xi'an, China, specializing in the development of innovative peptide-based therapeutics. The company leverages its proprietary peptide drug discovery and optimization platform to create high-potency, long-acting treatments for chronic and acute conditions. Maccote's primary therapeutic focus includes metabolic diseases such as type 2 diabetes and obesity, as well as cardiovascular and cerebrovascular diseases. Its lead candidate, MT-1002, is a triple agonist targeting the GLP-1, GIP, and glucagon receptors, currently undergoing Phase 2 clinical trials. The company has secured significant venture capital backing from prominent firms like Northern Light Venture Capital and Legend Capital to advance its clinical pipeline. Maccote aims to address significant unmet medical needs by providing next-generation peptide drugs with improved efficacy and safety profiles.